Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27354476

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2016 Nov 1
First author
Armand P

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2016 Jul 20;13(8):466. doi: 10.1038/nrclinonc.2016.114.
    note
    Source null
    related pmid
    27435267
    relationship
    Comment in
  2. citation
    Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1396-1399. doi: 10.1016/j.ijrobp.2018.05.079.
    note
    Source null
    related pmid
    31014778
    relationship
    Comment in

Authors and identifiers

  1. name
    Armand P
    type
    Author
  2. name
    Shipp MA
    type
    Author
  3. name
    Ribrag V
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Zinzani PL
    type
    Author
  6. name
    Kuruvilla J
    type
    Author
  7. name
    Snyder ES
    type
    Author
  8. name
    Ricart AD
    type
    Author
  9. name
    Balakumaran A
    type
    Author
  10. name
    Rose S
    type
    Author
  11. name
    Moskowitz CH
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Armand P
    type
    Author
  2. name
    Shipp MA
    type
    Author
  3. name
    Ribrag V
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Zinzani PL
    type
    Author
  6. name
    Kuruvilla J
    type
    Author
  7. name
    Snyder ES
    type
    Author
  8. name
    Ricart AD
    type
    Author
  9. name
    Balakumaran A
    type
    Author
  10. name
    Rose S
    type
    Author
  11. name
    Moskowitz CH
    type
    Author
bibliography ids
  1. nci-bib-11cebecbb2252229d9283b4b
book metadata
content sha256
3a1f267a12bd0ebdb1bdfd4293bc3cd3d1d66cbac872820d83be151680ff1685
document type
citation
dois
  1. 10.1200/JCO.2016.67.3467
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:27354476
immutable id
pubmed:27354476@3a1f267a12bd0ebdb1bdfd4293bc3cd3d1d66cbac872820d83be151680ff1685
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
31
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3733-3739
volume
34
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2016 Jul 20;13(8):466. doi: 10.1038/nrclinonc.2016.114.
    note
    Source null
    related pmid
    27435267
    relationship
    Comment in
  2. citation
    Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1396-1399. doi: 10.1016/j.ijrobp.2018.05.079.
    note
    Source null
    related pmid
    31014778
    relationship
    Comment in
outcomes validated
false
pmid
27354476
provenance
batch id
d649bcb2d98dbbacd53c
provider
NCBI PubMed ESummary
record sha256
180db5a282cab4d5e38f95d52636ffb12b304b887804c4b31baea834894cb48d
response sha256
26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
retrieved at
2026-09-09T23:47:20.761544+00:00
publication date
display
2016 Nov 1
precision
day
year
2016
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27354476/
title
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Preserved source evidence · Not medical advice